Industry News
Encouraging trial results for Prima’s ovarian cancer treatment
Prima BioMed (ASX:PRR) has published a second set of encouraging early data from a phase II trial of CVac in ovarian cancer [ + ]
Viralytics R&D Tax rebate higher than expected
Viralytics (ASX:VLA) has received nearly $1.5m as an R&D Tax Incentive rebate, and will plough the funds back into its oncolytic virus clinical development. [ + ]
Vic Gov launches Technology Voucher Program
Growing on the success of the “Small Technologies Industry Uptake Program” the Victorian Government has launched a new “Technology Voucher Program” (TVP). [ + ]
Feature: Wired to think
Australian neuroscientist Professor Seth Grant, FRS, is transforming neuroscience by revealing the startling complexity of the synaptic proteome. [ + ]
Biotron up after phase II HIV/HCV trial kicks off
Biotron (ASX:BIT) has commenced a pivotal phase II trial of BIT225 in patients with both HIV and HCV. [ + ]
Viralytics trial shows Cavatak well-tolerated
Viralyrics (ASX:VLA) has published results from a phase I trial showing anti-cancer virus, Cavatak, show the treatment was well-tolerated. [ + ]
Photonz seeking partners to develop drug manufacturing process
After years in development, New Zealand's Photonz is embarking on the hunt for partners to help commercialise its manufacturing process for a key cardiovascular drug component. [ + ]
New Australian telescope set to find 700,000 galaxies
Australia’s newest radio telescope is predicted to find an unprecedented 700,000 new galaxies, say scientists planning for CSIRO’s next-generation Australian Square Kilometre Array Pathfinder (ASKAP). [ + ]
UNE herbarium records to join national online database
An event at the University of New England (UNE) last month marked the beginning of a new era of research on the plants of north-eastern NSW and the UNE’s contribution to botany. [ + ]
Stealing nature’s photosynthetic secrets
The prospect of creating clean, renewable hydrogen fuel is closer than ever after a breakthrough in our understanding of photosynthesis. [ + ]
BioDiem, Griffith Uni team for BDM-1 research
BioDiem (ASX:BDM) will collaborate with Griffith University's Institute of Glycomics to explore increasing the solubility of antimicrobial compound BDM-1. [ + ]
Garvan team solve autoimmune mystery
A team at the Garvan Institute has solved a longstanding mystery as to how some autoimmune diseases can be triggered by wayward B cells. [ + ]
Government IP report promotes research and business collaboration
A report issued today by the Advisory Council on Intellectual Property has recommended reforming incentives to encourage researchers to collaborate with business. [ + ]
New drug target found for cystic fibrosis lung disease
Vancouver researchers have discovered the cellular pathway that causes lung-damaging inflammation in cystic fibrosis (CF), and that reducing the pathway’s activity also decreases inflammation. The finding offers a potential new drug target for treating CF lung disease. [ + ]
RNA detection from ultrasmall sample in only 20 minutes
A power-free microfluidic chip developed by researchers at the RIKEN Advanced Science Institute (ASI) enables detection of microRNA from extremely small sample volume in only 20 minutes. [ + ]
